Navigation Links
Amarantus BioScience and Banyan Biomarkers to Present Poster of MANF Data at The 3rd Annual Traumatic Brain Injury Conference
Date:2/25/2013

SUNNYVALE, Calif. and ALACHUA, Fla., Feb. 25, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI,  today announced that the companies will be making a joint poster presentation March 6-7, 2013 at The 3rd Annual Traumatic Brain Injury (TBI) Conference in Washington, DC (www.tbiconference.com). The poster is entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) neuroprotection from necrotic and apoptotic cell death in rat cortical cultures."

"MANF significantly inhibited caspase and calpain-mediated cellular processes of cell death and conferred overall neuroprotection in our cellular model systems of TBI," said Dr. Juan Martinez , Director of Scientific Operations at Banyan Biomarkers.  "This neuroprotection indicates therapeutic potential based on well-defined biochemical pathway inhibition. We look forward to working with Amarantus to further develop MANF's therapeutic potential in TBI."

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amara
'/>"/>

SOURCE Amarantus Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015 First Harvest Financial ... leading source for advice to legal medical cannabis companies. ... and strategic planning to start-ups and entrepreneurs, First Harvest ... industry. , Wall Street veteran, Kevin Gillespie, has ... President and Portfolio Manager. Due to early success ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Spartan Bioscience ... founder, has been selected by the Ottawa Chamber of ... 40. Dr. Lem was selected from over 240 applicants ... involvement. , Prior to Spartan, Dr. Lem founded Plexagen ... DNA Genotek. He holds a Medical Degree from the ...
(Date:4/28/2015)... 2015 The Alliance for Clinical ... non-profit organization dedicated to transforming the medical products ... system for clinical research, announced today that it ... type of clinical research event in Boston, October ... is changing,” said Greg Koski, PhD, MD, Co-founder ...
(Date:4/27/2015)... VANCOUVER , April 27, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the year ... are expressed in Canadian dollars and presented under ... year,s phase two DME results did not provide ... but extremely undervalued assets remain at iCo Therapeutics", ...
Breaking Biology Technology:Leading Medical Cannabis Advisor, First Harvest Financial, Welcomes Top Executives Aboard 2Leading Medical Cannabis Advisor, First Harvest Financial, Welcomes Top Executives Aboard 3Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4
... Inc., a privately held company developing and commercializing novel ... for new and existing therapeutics, announced today that Edward ... presenting at the Annual UBS Global Life Sciences Conference ... City on Tuesday, September 20, 2011 at 12:30 p.m. ...
... , Chemosaturation Demonstrates Clinically Meaningful Tumor ... Delcath Systems, Inc. (NASDAQ: DCTH ... tumor (mNET) cohort of the Company,s recently completed Phase ... and Interventional Radiological Society of Europe (CIRSE) congress ...
... to be installed at the Rensselaer Polytechnic Institute ... across the nation and boost the university,s international ... high-performance computing, and web science. Funded ... Science Foundation (NSF) and with additional support from ...
Cached Biology Technology:Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 3Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 4Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 5New supercomputer to boost Rensselaer leadership in high-performance computing 2New supercomputer to boost Rensselaer leadership in high-performance computing 3New supercomputer to boost Rensselaer leadership in high-performance computing 4
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... A joint Yale-Peking University center that aims to ... will receive five years of continued and expanded support ... technology. The company will fund student exchanges and ... Peking-Yale Joint Center (PYC) for Plant Molecular Genetics and ...
... in children,s blood -- amounts well below the current ... finds a new six-year Cornell study., The study examined ... children whose blood-lead levels (BLLs) were below the Centers ... micrograms per deciliter (mcg/dl) -- about 100 parts per ...
... N.Y. Single-molecule biologythe revolutionary field that deals ... Tremendous technical advances have made it possible to ... images as they twist, twirl, wobble, and unfold. ... book that was just released by Cold Spring Harbor ...
Cached Biology News:Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2Even minute levels of lead cause brain damage in children 2New book presents methods to poke and prod individual molecules 2
... yellow solution. In PBS ... and other proprietary stabilizers; ... formulated to stabilize activity ... conjugates at high conjugate ...
... Gene Pulser Xcell eukaryotic system, ... Hz, is used for electroporation ... includes the main unit, CE ... range) or square-wave pulses, ShockPod ...
... software is used on Macintosh operating ... of any DNA sequence up to ... placement of primers and GC clamps ... gel electrophoresis (DGGE), constant denaturing gel ...
... Services offer you a full range ... B-Bridges advanced design parameters, effective synthetic ... that you obtain quality results from ... Service utilizes their proprietary B-Algo algorithm ...
Biology Products: